Accès gratuit
Numéro
Med Sci (Paris)
Volume 33, Numéro 4, Avril 2017
Page(s) 410 - 416
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20173304011
Publié en ligne 12 mai 2017
  1. Arnaud I, Jarlier V, groupe de travail BMR-RAISIN. Surveillance des bactéries multirésistantes dans les établissements de santé en France. Réseau BMR-RAISIN, résultats 2013. Saint-Maurice : Institut de Veille Sanitaire (InVS), 2015.
  2. Colomb-Cotinat M, Lacoste J, Coignard B, et al. Morbidité et mortalité des infections à bactéries multi-résistantes aux antibiotiques en France en 2012. Étude Burden BMR. Saint-Maurice : Institut de Veille Sanitaire (InVS), 2015.
  3. Center for Disease Control. Antibiotic resistance threats in the United States. Atlanta : CDC, 2013.
  4. Carlet J. The gut is the epicentre of antibiotic resistance. Antimicrob Resist Infect Control 2012 ; 1 : 39. [CrossRef] [PubMed]
  5. Carlet J, Le Coz P. Rapport du groupe de travail spécial pour la préservation des antibiotiques. Paris : Ministère des Affaires sociales, de la Santé et des Droits des femmes, 2015.
  6. Nobrega FL, Costa AR, Kluskens LD, Azeredo J. Revisiting phage therapy: new applications for old resources. Trends Microbiol 2015 ; 23 : 185–191. [CrossRef] [PubMed]
  7. Chibani-Chennoufi S, Bruttin A, Dillmann ML, Brussow H. Phage-host interaction: an ecological perspective. J Bacteriol 2004 ; 186 : 3677–3686. [CrossRef]
  8. Rohwer F. Global phage diversity. Cell 2003 ; 113 : 141. [CrossRef]
  9. Letarov A, Kulikov E. The bacteriophages in human- and animal body-associated microbial communities. J Appl Microbiol 2009 ; 107 : 1–13. [CrossRef] [PubMed]
  10. Suttle CA. The significance of viruses to mortality in aquatic microbial communities. Microb Ecol 1994 ; 28 : 237–243. [CrossRef] [PubMed]
  11. Koskella B, Brockhurst MA. Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities. FEMS Microbiol Rev 2014 ; 38 : 916–931. [CrossRef] [PubMed]
  12. d’Herelle F. Sur un microbe invisible antagoniste des bacilles dysentériques. CR Acad Sci Paris 1917 ; 165 : 373–375.
  13. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011 ; 1 : 66–85. [CrossRef] [PubMed]
  14. Pires DP, Oliveira H, Melo LD, et al. Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol 2016 ; 100 : 2141–2151. [CrossRef]
  15. Abedon ST. Phage therapy of pulmonary infections. Bacteriophage 2015 ; 5 : e1020260.
  16. Saussereau E, Debarbieux L. Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice. Adv Virus Res 2012 ; 83 : 123–141. [CrossRef] [PubMed]
  17. Dufour N, Debarbieux L, Fromentin M, Ricard JD. Treatment of highly virulent extraintestinal pathogenic Escherichia coli pneumonia with bacteriophages. Crit Care Med 2015 ; 43 : e190–e198. [CrossRef] [PubMed]
  18. Debarbieux L, Leduc D, Maura D, et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 2010 ; 201 : 1096–1104. [CrossRef] [PubMed]
  19. Dufour N, Henry M, Ricard JD, Debarbieux L. Commentary: morphologically distinct Escherichia coli bacteriophages differ in their efficacy and ability to stimulate cytokine release in vitro. Front Microbiol 2016 ; 7 : 1029. [CrossRef] [PubMed]
  20. Speck P, Smithyman A. Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett 2016 ; 363.
  21. Comeau AM, Tetart F, Trojet SN, et al. Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2007 ; 2 : e799. [CrossRef]
  22. Samson JE, Magadan AH, Sabri M, Moineau S. Revenge of the phages: defeating bacterial defences. Nat Rev Microbiol 2013 ; 11 : 675–687. [CrossRef]
  23. Dy RL, Richter C, Salmond GPC, Fineran PC. Remarkable mechanisms in microbes to resist phage infections. Annu Rev Virol 2014 ; 1 : 307–331. [CrossRef] [PubMed]
  24. Stern A, Sorek R. The phage-host arms race: shaping the evolution of microbes. Bioessays 2011 ; 33 : 43–51. [CrossRef]
  25. Capparelli R, Nocerino N, Iannaccone M, et al. Bacteriophage therapy of Salmonella enterica: a fresh appraisal of bacteriophage therapy. J Infect Dis 2010 ; 201 : 52–61. [CrossRef] [PubMed]
  26. Hung CH, Kuo CF, Wang CH, et al. Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother 2011 ; 55 : 1358–1365. [CrossRef] [PubMed]
  27. Pouillot F, Chomton M, Blois H, et al. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother 2012 ; 56 : 3568–3575. [CrossRef] [PubMed]
  28. Chan BK, Sistrom M, Wertz JE, et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 2016 ; 6 : 26717. [CrossRef] [PubMed]
  29. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 2005 ; 49 : 2874–2878. [CrossRef] [PubMed]
  30. McCallin S, Alam Sarker S, Barretto C, et al. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology 2013 ; 443 : 187–196. [CrossRef] [PubMed]
  31. Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, et al. Clinical aspects of phage therapy. Adv Virus Res 2012 ; 83 : 73–121. [CrossRef] [PubMed]
  32. Miernikiewicz P, Dabrowska K, Piotrowicz A, et al. T4 phage and its head surface proteins do not stimulate inflammatory mediator production. PLoS One 2013 ; 8 : e71036. [CrossRef] [PubMed]
  33. Dabrowska K, Miernikiewicz P, Piotrowicz A, et al. Immunogenicity studies of proteins forming the T4 phage head surface. J Virol 2014 ; 88 : 12551–12557. [CrossRef] [PubMed]
  34. Ochs HD, Buckley RH, Kobayashi RH, et al. Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. Blood 1992 ; 80 : 1163–1171.
  35. Zaczek M, Lusiak-Szelachowska M, Jonczyk-Matysiak E, et al. Antibody production in response to staphylococcal MS-1 phage cocktail in patients undergoing phage therapy. Front Microbiol 2016 ; 7 : 1681. [CrossRef] [PubMed]
  36. Ando H, Lemire S, Pires DP, Lu TK. Engineering modular viral scaffolds for targeted bacterial population editing. Cell Systems 2015 ; 1 : 187–196. [CrossRef] [PubMed]
  37. Barbu EM, Cady KC, Hubby B. Phage therapy in the era of synthetic biology. Cold Spring Harb Perspect Biol 2016 ; 8. [PubMed]
  38. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa: a preliminary report of efficacy. Clin Otolaryngol 2009 ; 34 : 349–357. [CrossRef] [PubMed]
  39. Sarker SA, Sultana S, Reuteler G, et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 2016 ; 4 : 124–137. [CrossRef] [PubMed]
  40. Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 2014 ; 27 : 543–574. [CrossRef]
  41. Dufour N, Clermont O, La Combe B, et al. Bacteriophage LM33_P1, a fast-acting weapon against the pandemic ST131-O25b:H4 Escherichia coli clonal complex. J Antimicrob Chemother 2016 ; 71 : 3072–3080. [CrossRef]
  42. Galtier M, De Sordi L, Maura D, et al. Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition. Environ Microbiol 2016 ; 18 : 2237–2245. [CrossRef] [PubMed]
  43. Martinez-Medina M, Garcia-Gil LJ. Escherichia coli in chronic inflammatory bowel diseases: an update on adherent invasive Escherichia coli pathogenicity. World J Gastrointest Pathophysiol 2014 ; 5 : 213–227.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.